Cambium Bio (ASX:CMB) — Material Events
ASX:CMB · 9 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Cambium Bio Advances Elate Ocular Phase 3 Trial with FDA Single Pivotal Study Pathway amid AUD 4.1M LossMedium
Cambium Bio advances Elate Ocular Phase 3 trial with FDA single pivotal study pathway amid AUD 4.1M loss
28 Aug 2026
·Preliminary Final Report and Annual Report
·85
Cambium Bio Advances Phase 3 Trials with Strategic Deals and Fresh FundingHigh
Cambium Bio advances Phase 3 trials, secures strategic partnerships and funding, reports reduced half-year loss
20 Feb 2026
·Half-Year Financial Report
·85
Cambium Bio Secures $3M Funding Boost to Propel Phase 3 TrialsMedium
Cambium Bio secures A$0.6M R&D refund and A$2.4M strategic placement to advance Phase 3 trials
23 Jan 2026
·Quarterly Cashflow Report & Business Update
·85
Cambium Bio Secures FDA Nod for Single-Trial Phase 3 and Raises A$2.4M from Major ShareholderHigh
Cambium Bio advances Phase 3 readiness with FDA single-trial pathway confirmation and A$2.4M strategic placement
28 Apr 2026
·Quarterly Cashflow Report & Business Update
·85
Cambium Bio Secures $2.17M Capital Raise and Strategic Deals to Propel Phase 3 TrialsMedium
Cambium Bio secures R&D tax rebate, strategic partnerships, and completes capital raise to advance Phase 3 trials
27 Oct 2025
·Quarterly Cashflow Report & Business Update
·85
Cambium Bio Expands Reach with Benta SAS for Elate Ocular in Europe and Middle EastMedium
Cambium Bio inks strategic MoU with Benta SAS to commercialise Elate Ocular in Europe and Middle East
5 Sept 2025
·Strategic Partnership Announcement
·85
Cambium Bio Secures A$2.4M Boost from Major Shareholder for Phase 3 TrialsMedium
Cambium Bio Raises A$2.4M from Major Shareholder to Fund Phase 3 Trials
20 Jan 2026
·Capital Raising
·80
Cambium Bio Secures A$1 Million Placement at Premium to Fund Phase 3 TrialMedium
Cambium Bio Raises A$1 Million via Placement to Strategic Shareholder for Phase 3 Trial
22 July 2026
·Capital Raising
·75
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Cambium Bio (ASX:CMB) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Market Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026